Arthneeti
All Q2 FY27 results →
DL

Dr Lal Pathlabs Ltd

Q2 FY27Healthcare Services

Dr Lal Pathlabs Q2 Results 2026 (FY27) investor presentation: Revenue & Margins

Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.

Price₹1,926
Market cap₹32.3K Cr
P/E57.5
Updated4 Nov 2026
Read2 min read

Dr Lal Pathlabs Ltd Q2 FY27 key numbers

Revenue
Q2 FY27 Samples: 9.0 million, up 13.6% YoY from 8.2 million.

As stated in Dr Lal Pathlabs Ltd's Q2 FY27 investor presentation · published 4 Nov 2026. Reported figures, not investment advice.

Based on Dr Lal Pathlabs Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

The short version

Q2 FY27 Revenue: Rs. 874 Cr, up 19.6% YoY from Rs. 731 Cr in Q2 FY26 (Page 8, 9, 6). Q2 FY27 Financial Figures:.

From Dr Lal Pathlabs Ltd's Q2 FY27 earnings-call transcript · updated 4 Nov 2026.

How did Dr Lal Pathlabs' revenue grow in the September 2026 quarter?

  • Q2 FY27 Revenue: Rs. 874 Cr, up 19.6% YoY from Rs. 731 Cr in Q2 FY26 (Page 8, 9, 6)
  • Q2 FY27 Samples: 9.0 million, up 13.6% YoY from 8.2 million (Page 6, 9)
  • Q2 FY27 Patients: 28.8 million, up 9.0% YoY from 25.4 million (Page 6, 9)
  • H1 FY27 Revenue: Rs. 1,672 Cr, up 19.4% YoY (Page 7)

2 more points from Dr Lal Pathlabs Ltd's call on revenue

Create a free account to keep reading this call

What happened to Dr Lal Pathlabs' margins in Q2 FY27?

See what Dr Lal Pathlabs Ltd said on profitability & margins — free account, 30 seconds.

What capex is Dr Lal Pathlabs planning?

Key points related to infrastructure and investments mentioned are: - Installed 42 KW Solar System to generate green energy within existing 3.18 MW base (Page 29). - Use of electric bikes and biodegradable bags for sample collection as sustainability initiatives (Page 29).

2 more points from Dr Lal Pathlabs Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
1Health X Platform
Rev 1Mar 1
2Chandan Healthca
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 2
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Is Dr Lal Pathlabs raising money or cutting debt?

See what Dr Lal Pathlabs Ltd said on fundraising & capital structure — free account, 30 seconds.

How big is Dr Lal Pathlabs' order book?

See what Dr Lal Pathlabs Ltd said on order book & pipeline — free account, 30 seconds.

Dr Lal Pathlabs Ltd — Quarterly revenue & net profit

Revenue Net profit
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27

Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the analysis on this page.

Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹798 Cr, net profit ₹170 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Dr Lal Pathlabs Ltd's management said in earlier quarters

Others in Healthcare Services this season

  • Vimta Labs (Q2 FY27)

    Export-import linked food testing volumes recovering with operations reaching 60%-70% of normal levels. Key concall takeaways from Vimta Labs Ltd's Q2 FY27…

  • Vijaya Diagnostic Centre (Q2 FY27)

    Q2 FY27 Revenue from Operations: INR 2,554 Mn, up 26.7% YoY (Page 10, 9) . Key investor presentation takeaways from Vijaya Diagnostic Centre Ltd's Q2 FY27 inves

  • Shalby (Q2 FY27)

    Consolidated Total Revenue for Q2 FY27: ₹3,182 million vs ₹2,899 million in Q2 FY26, up 9.8% YoY (Pages 5, 6, 8, 9) . Key investor presentation takeaways from S

  • Metropolis Healt (Q2 FY27)

    Q2FY27 revenue from operations: INR 496.8 Cr, up 15.8% YoY (Page 11) . Key investor presentation takeaways from Metropolis Healthcare Ltd's Q2 FY27 investor pre

Compare:vs Apollo Hospitalsvs Max Healthcarevs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Dr Lal Pathlabs Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Dr Lal Pathlabs Ltd Q2 FY27 results?

Q2 FY27 Revenue: Rs. 874 Cr, up 19.6% YoY from Rs. 731 Cr in Q2 FY26 (Page 8, 9, 6). Q2 FY27 Financial Figures:.

What is Dr Lal Pathlabs Ltd share price analysis?

Dr Lal Pathlabs Ltd currently shows a neutral. The stock trades at a P/E of 57.5 with a market cap of ₹32,326 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Dr Lal Pathlabs Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.